TMS can cause temporary scalp discomfort or headache, and seizure is its most serious potential adverse effect; international guidelines describe seizure risk as low with standard parameters and focal coils. Whether TMS is appropriate for you depends on a prescriber's review of your health history, medications, implanted devices, and proposed treatment protocol—not a promise that treatment is risk-free (international safety guidelines).
For people considering TMS in New Jersey, a useful safety conversation should explain both what you may feel during treatment and which personal factors require additional assessment.
What the international safety guidelines say
The international expert guidelines address TMS safety across patient populations and research settings. Their central message about seizures is reassuring but conditional: risk is low when standard stimulation parameters and focal coils are used, including in patients taking medications that act on the central nervous system (international safety guidelines).
“Low risk” does not mean “no risk.” It also should not be interpreted as a single risk estimate that applies equally to every device, protocol, or patient. Ask the prescriber how the proposed treatment fits established safety guidance and whether anything in your history changes the assessment.
Safety and regulatory status are separate questions. The original NeuroStar clearance covered adults with major depressive disorder who had not improved after an adequate antidepressant trial; it was not a blanket clearance for every condition or protocol (FDA clearance document). Your consultation should identify whether the proposed use falls within the particular device's FDA-cleared labeling or is off-label.
Common, short-lived side effects
Scalp discomfort and headache are recognized TMS side effects. The tapping sensation can be uncomfortable, and stimulation may cause nearby facial or scalp muscles to contract. These effects are generally temporary, but their intensity differs between people (international safety guidelines).
Tell the treatment team about discomfort rather than assuming you must tolerate it silently. They can assess coil positioning, review stimulation settings within the prescribed protocol, and discuss appropriate symptom management. Ask the prescriber before taking medication specifically to manage treatment-related headaches.
A sham-controlled depression trial reported that 4.5% of participants discontinued because of side effects. That finding provides context about tolerability, but it does not predict how an individual will feel or establish the same tolerability for every TMS protocol (multisite randomized controlled trial).
A practical plan should distinguish expected discomfort from symptoms needing assessment. Ask whom to contact for a headache that persists, worsening pain, dizziness, or symptoms that feel different from what the team described. Severe or unusual symptoms should not automatically be attributed to TMS.
Seizure risk: screening matters
Seizure is the most serious potential adverse effect highlighted by the safety guidelines, although the risk is low under standard treatment conditions. A personal or family seizure history and other neurological risk factors deserve review before treatment (international safety guidelines).
The screening conversation should include:
- Any previous seizure, epilepsy diagnosis, or unexplained loss of consciousness.
- Significant head injury, stroke, or other neurological illness.
- Prescription medications, over-the-counter products, and supplements.
- Alcohol or other substance use, including recent changes or withdrawal.
- Sleep disruption and any recent changes in general health.
These details help the prescriber assess the whole clinical picture. Having a risk factor is not necessarily the same as having an absolute contraindication; it may call for additional review, coordination with another clinician, or a different treatment decision.
Do not stop psychiatric medication on your own to prepare for TMS. The guidelines' low-risk finding includes patients taking central nervous system–active medication, but medication changes still belong in an individualized safety assessment (international safety guidelines). Tell the team about changes during the treatment course, not just at intake.
Who should not have TMS—or needs further assessment?
There is no responsible universal exclusion list that replaces the specific device's labeling and a medical evaluation. Some implants or metallic objects near the treatment coil can present hazards involving magnetic forces, heating, or interference with electronic function. Their material, location, and device specifications matter (international safety guidelines).
Disclose implanted electronic devices, cochlear implants, surgical clips, retained metal fragments, and any other implant. Bring an implant identification card or surgical records if available. A potentially incompatible implant should be evaluated before treatment proceeds; patients should not have to judge compatibility themselves.
Routine dental work is not automatically equivalent to a hazardous implant. Even so, disclose it and let the team apply the relevant device instructions. Similarly, a device elsewhere in the body requires an appropriate compatibility check rather than an assumption that distance alone settles the question.
A history of seizures, neurological illness, or a substantial change in medication or substance use calls for careful assessment, not an automatic yes or no. Tell the prescriber if you are pregnant or could be pregnant, and discuss any history of mania or hypomania as part of the psychiatric evaluation.
The important question is not simply, “Am I excluded?” It is, “What information does the prescriber need to decide whether this particular treatment can be offered safely?”
Hearing protection and session preparation
TMS coils produce a loud clicking sound, and the safety guidelines recommend appropriate hearing protection. Ask how the team checks that protection fits and what to do if you notice ringing, ear pain, or a hearing change (international safety guidelines).
Before treatment, confirm how to report changes in sleep, medications, alcohol use, or health. Ask whether these are reviewed before each session and who decides if a new concern requires postponement or reassessment.
If you are traveling from Princeton or Jersey City, include appointment logistics in that conversation. Ask about scheduling, whom to call if you feel unwell before leaving home, and how to reach the prescriber between visits. Clear instructions matter more than a reassuring slogan about safety.
Questions to ask before your first session
Bring a written list so the discussion covers your concerns as well as the team's intake questions:
- What device and protocol are you proposing? Is this use within its FDA-cleared labeling, or is it off-label?
- What in my history affects safety? Have my medications, neurological history, and implants been reviewed?
- What should treatment feel like? How will you respond if scalp discomfort or headache becomes difficult to tolerate?
- How is hearing protected? What symptoms should I report immediately?
- Who oversees my care? Who operates the device, and how can they reach the prescribing clinician?
- What is the emergency plan? How are staff prepared to recognize and respond to a seizure or another medical event?
- What changes should I report? Ask specifically about missed medication, new prescriptions, poor sleep, and illness.
- How will you monitor my mental health? Clarify how to report worsening mood, agitation, or unusual changes in sleep and energy.
For background, see our answers to common TMS questions. Our depression information page can help frame a discussion about the condition being treated, while the New Jersey provider directory can help you find a prescriber for an individualized consultation.
A useful consultation leaves you knowing the proposed treatment's regulatory status, your personal precautions, and how concerns will be handled. That is a stronger basis for informed consent than either dismissing risks or assuming every warning means TMS is unsuitable.
References
- O'Reardon JP et al. Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry, 2007. PMID 17573044
- US FDA 510(k) clearance K083538 (NeuroStar TMS System), 2008
- Rossi S et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert guidelines. Clinical Neurophysiology, 2021. PMID 33243615